Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)

anxiety

Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)

ONLY AVAILABLE IN PAID PLANS.

Originally reported by rutlandherald. Read more

Source: https://www.rutlandherald.com/news/business/merck-and-eisai-provide-update-on-phase-3-litespark-012-trial-evaluating-first-line-combination/article_96229ead-e9d2-5749-beb3-16a5a1fe1a0f.html